These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 8761367)

  • 1. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
    Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A
    Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
    Vassal G; Pondarré C; Cappelli C; Terrier-Lacombe MJ; Boland I; Morizet J; Bénard J; Vénuat AM; Ardouin P; Hartmann O; Gouyette A
    Eur J Cancer; 1997 Oct; 33(12):2011-5. PubMed ID: 9516844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
    Calvet L; Santos A; Valent A; Terrier-Lacombe MJ; Opolon P; Merlin JL; Aubert G; Morizet J; Schellens JH; Bénard J; Vassal G
    Br J Cancer; 2004 Sep; 91(6):1205-12. PubMed ID: 15292932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
    Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
    Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
    Santos A; Calvet L; Terrier-Lacombe MJ; Larsen A; Bénard J; Pondarré C; Aubert G; Morizet J; Lavelle F; Vassal G
    Cancer Res; 2004 May; 64(9):3223-9. PubMed ID: 15126363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of oral irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
    Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
    Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
    Komuro H; Li P; Tsuchida Y; Yokomori K; Nakajima K; Aoyama T; Kaneko M; Kaneda N
    Med Pediatr Oncol; 1994; 23(6):487-92. PubMed ID: 7935175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.
    Boland I; Vassal G; Morizet J; Terrier-Lacombe MJ; Valteau-Couanet D; Kalifa C; Hartmann O; Gouyette A
    Br J Cancer; 1999 Feb; 79(5-6):787-92. PubMed ID: 10070870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
    Hare CB; Elion GB; Houghton PJ; Houghton JA; Keir S; Marcelli SL; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1997; 39(3):187-91. PubMed ID: 8996518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.
    Meco D; Di Francesco AM; Cusano G; Bucci F; Pierri F; Patriarca V; Torella AR; Pisano C; Riccardi R
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):811-22. PubMed ID: 23007316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.
    Miki T; Sawada M; Nonomura N; Kojima Y; Okuyama A; Maeda O; Saiki S; Kotake T
    Eur Urol; 1997; 31(1):92-6. PubMed ID: 9032542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
    Kaneko M; Kaneko S; Suzuki K
    Cancer Sci; 2009 Nov; 100(11):2193-201. PubMed ID: 19673886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
    Vassal G; Pondarré C; Boland I; Cappelli C; Santos A; Thomas C; Lucchi E; Imadalou K; Pein F; Morizet J; Gouyette A
    Biochimie; 1998 Mar; 80(3):271-80. PubMed ID: 9615866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
    Kaneko S; Ishibashi M; Kaneko M
    Cancer Sci; 2008 Jun; 99(6):1209-17. PubMed ID: 18384433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma].
    Hirota T; Kawai N; Kitagawa S; Hori T; Konno K; Sawada K; Agata H; Fujimoto T; Tsurusawa M
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2049-54. PubMed ID: 11791383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.